Browse News

Found 44 articles

• Viridian Therapeutics to Participate in the JMP Securities Life Sciences Conference

  6/10/2021

  Viridian Therapeutics, Inc. (Nasdaq: VRDN), today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will participate in a fireside chat at the virtual JMP Securities Life Sciences Conference

• Viridian Therapeutics to Participate in Upcoming Investor Conferences - May 14, 2021

  5/14/2021

  Viridian Therapeutics, Inc. announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will present a company overview at the virtual Oppenheimer Rare & Orphan Disease Summit and participate in a fireside chat at the Jefferies Virtual Healthcare Conference.

• Akerna Announces Financial Results for the First Quarter 2021

  5/10/2021

  Akerna (Nasdaq: KERN), an enterprise software, leading compliance technology provider and developer of the cannabis industry's first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), today reported its unaudited financial results for the quarter ended March 31, 2021.

• Viridian Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Updates

  5/6/2021

  Viridian Therapeutics, Inc., a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by current therapies, announced financial results for the first quarter of 2021 and provided corporate updates.

• Akerna to Announce Financial Results for the First Quarter 2021 Ended March 31, 2021

  5/4/2021

  Akerna (Nasdaq: KERN), an enterprise software, leading compliance technology provider and developer of the cannabis industry's first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), will report financial results for the first quarter ended March 31, 2021, on Monday, May 10, 2021.

• Akerna closes acquisition of Viridian Sciences

  4/6/2021

  Akerna (Nasdaq: KERN) ("Akerna" or the "Company"), an enterprise software company, leading compliance technology provider, and developer of the cannabis industry's first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®),  today announces it has closed the acquisition of Viridian Sciences,

• Viridian Therapeutics Reports 2020 Financial Results and Provides Corporate Updates

  3/25/2021

  Progressed lead programs VRDN-001 and VRDN-002 towards clinical trials in Thyroid Eye Disease (TED); both IND filings expected by the end of 2021 Completed integration and name change to Viridian Therapeutics following October 2020 merger and concurrent financing

• 

  From Hong Kong to Boston, New Biopharma Launches with Immune-based Pipeline

  3/23/2021

  Zenas BioPharma announced it has launched a cross-border biopharmaceutical company based in both China and the U.S.

• Zenas BioPharma Launches as a Cross-Border Biopharmaceutical Company to Bring Innovation to the Development and Delivery of Immune-Based Therapies

  3/23/2021

  Rapidly advancing seven pipeline programs, including three worldwide, with best-in-class potential in autoimmune and rare diseases

• Akerna Announces Financial Results for the Quarter Ended December 31, 2020

  3/22/2021

  Akerna (Nasdaq: KERN), an enterprise software, leading compliance technology provider and developer of the cannabis industry's first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), today reported its unaudited financial results for the quarter ended December 31, 2020.

• Akerna to Acquire Viridian Sciences

  3/11/2021

  Akerna (Nasdaq: KERN) ("Akerna" or the "Company"), an enterprise software company, leading compliance technology provider, and developer of the cannabis industry's first seed-to-sale enterprise resource planning (ERP) software technology (MJ Platform®), announced it has signed an agreement to acquire Viridian Sciences,

• Viridian Therapeutics To Host Conference Call Discussing Fourth Quarter And Full Year 2020 Results And Corporate Update

  3/9/2021

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies, today announced that it will host a conference call and webcast on Thursday, March 25, 2021 at 4:30 p.m. ET to discuss a corporate update and results for the fourth quarter and full year 2020.

• Xencor Reports Fourth Quarter and Full Year 2020 Financial Results

  2/23/2021

  Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2020

• Viridian Therapeutics to Present at Three Upcoming Investor Conferences

  2/22/2021

  Viridian Therapeutics, Inc. (NASDAQ: VRDN), a development-stage biopharmaceutical company, today announced that Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian, will present a company overview at the following upcoming investor conferences: Event: SVB Leerink 10 TH Annual Global Healthcare Conference 2021 (Virtual) Date:  Wednesday, February 24 TH Presentation Time: 1:00 p.m. EST     

• Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc.

  1/29/2021

  Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that it has acquired Quellis Biosciences Inc. (“Quellis”), a privately-held emerging biopharmaceutical company focused on discovering best-in-class new molecules to treat serious rare diseases.

• 

  BioSpace Movers & Shakers, Jan. 22

  1/22/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• miRagen Therapeutics Announces Company Name Change to Viridian Therapeutics and New Executive Appointments, Including Expansion of Leadership Team

  1/19/2021

  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“Viridian”).

• miRagen Reports Third Quarter 2020 Financial Results and Provides Corporate Updates

  11/10/2020

  Recently completed acquisition of Viridian Therapeutics, including an anti-IGF-1R monoclonal antibody, VRDN-001, for the potential treatment of thyroid eye disease (TED) Private placement financing proceeds of approximately $91 million positions miRagen to potentially advance multiple compounds through Phase 2 proof of concept studies in TED and expand its orphan disease pipeline

• ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results

  11/6/2020

  Partnership with Huadong Medicine Accelerates Development and Commercialization of Mirvetuximab Soravtansine in Greater China Encouraging Anti-Tumor Activity and Tolerability Data from FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin ® in Platinum-Sensitive Ovarian Cancer Presented at ESMO FDA Breakthrough Therapy Designation Received for IMGN632 in Relapsed or Refractory BPDCN

• miRagen Therapeutics, Inc. Announces Acquisition of Viridian Therapeutics, Inc.

  10/28/2020

  Acquisition includes clinicalstage anti-IGF-1R monoclonal antibody, VRDN-001, intended for the treatment of thyroid eye disease (TED)